Showing results (111-120 of 144) with videos related to

Sort By:
Pageof 15
Thyroid : Official Journal of the American Thyroid Association|June 8, 2006
Interaction of HLA-DRB1 alleles with CTLA-4 in the predisposition to Graves' disease: the impact of DRB1*07Dorota Kula, Tomasz Bednarczuk, Beata Jurecka-Lubieniecka, et al.
International Journal of Molecular Sciences|June 3, 2017
Gene Expression (mRNA) Markers for Differentiating between Malignant and Benign Follicular Thyroid TumoursBartosz Wojtas, Aleksandra Pfeifer, Malgorzata Oczko-Wojciechowska, et al.
Scientific Reports|February 10, 2017
Differences in the transcriptome of medullary thyroid cancer regarding the status and type of RET gene mutationsMalgorzata Oczko-Wojciechowska, Michal Swierniak, Jolanta Krajewska, et al.
Thyroid : Official Journal of the American Thyroid Association|June 1, 2013
Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinomaJulie A Sosa, Rossella Elisei, Barbara Jarzab, et al.
Cancers|June 21, 2020
TERT Promoter Mutations and Their Impact on Gene Expression Profile in Papillary Thyroid CarcinomaDagmara Rusinek, Aleksandra Pfeifer, Marta Cieslicka, et al.
Lancet (London, England)|April 29, 2014
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trialMarcia S Brose, Christopher M Nutting, Barbara Jarzab, et al.
Folia Histochemica Et Cytobiologica|January 5, 2017
Ratio of proliferation markers and HSP90 gene expression as a predictor of pathological complete response in breast cancer neoadjuvant chemotherapyMichal Jarzab, Monika Kowal, Wieslaw Bal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 28, 2015
A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid CancerMartin Schlumberger, Barbara Jarzab, Maria E Cabanillas, et al.
Drug Design, Development and Therapy|September 15, 2015
Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analoguesEdward M Wolin, Barbara Jarzab, Barbro Eriksson, et al.
Frontiers in Endocrinology|July 17, 2024
Safety and efficacy of nintedanib as second-line therapy for patients with differentiated or medullary thyroid cancer progressing after first-line therapy. A randomized phase II study of the EORTC Endocrine Task Force (protocol 1209-EnTF)Sophie Leboulleux, Ellen Kapiteijn, Saskia Litière, et al.
Pageof 15